Is Baxter International (BAX) a risky stock?
As of July 27, 2026, Clavix grades Baxter International (BAX) D+ for risk, a composite score of 45 out of 100 on an A+ to F scale, which puts BAX in the "elevated risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 27, 2026. Clavix regrades every trading day.
BAX price, last 3 months
BAX's daily closes over the past three months. Clavix reads risk from the fundamentals and news behind the price, not the line itself.
The five risk dimensions behind BAX's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how BAX scores on each, as of July 27, 2026.
What's moving BAX's risk right now
Company-specific signals Clavix flags behind BAX's current grade, drawn from recent news and filings as of July 27, 2026.
Baxter recalled one lot of generic antibiotic cefazolin over quality issues, a small direct hit but raising manufacturing oversight questions. Separately, analysts cite soft demand, declining profitability, and poor capital allocation as ongoing concerns.
Analysts expect Baxter's Q2 earnings to decline, with results likely flat or below expectations. A miss could weigh on the stock short-term and signal broader operational challenges.
An early FDA alert flagged a potential safety issue with a Baxter intravascular administration set, which could trigger a recall or closer regulatory rating update. The IV solutions segment may face short-term revenue pressure.
Recent BAX news
The latest headlines Clavix ingested for Baxter International, newest first. These feed the news-sentiment dimension of BAX's grade.
-
Baxter International (NYSE: BAX) is voluntarily recalling a single lot (LD175708, exp. Feb 2027) of Cefazolin in Dextrose Injection after cardboard particulate matter was found in the solution. The recall is nationwide and covers 100mL single-dose infusion bags.
-
Baxter (BAX) is expected to report second-quarter results showing pressured earnings and sales due to manufacturing inefficiencies, inflation, and product holds, even though demand across its segments remained steady.
-
An earnings preview notes that Baxter International (BAX) is not expected to beat Q2 earnings estimates, as it lacks the combination of two key ingredients typically associated with a positive earnings surprise. The report suggests investors prepare for likely below-expectation Q2 results.
What a D+ grade means
On the Clavix A+ to F scale, BAX's composite of 45 falls in the D band (35–49), read as "elevated risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell BAX or any security. Grades are risk indicators, not predictions of return. Data may be delayed.